Narodny ustav reumatickych chorob

Piešťany 92112

2 studies enrolling now · 13 studies all time

What they study most

Active Idiopathic Inflammatory Myopathy, Ankylosing Spondyloarthritis, Antisynthetase Syndrome, Arthritis, Rheumatoid, Chronic Cutaneous Lupus Erythematosus, Dermatomyositis, Immune-Mediated Necrotizing Myopathy, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Systemic, Myositis, Osteoarthritis, Polymyositis

Studies at this site

• A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus — Recruiting now
• A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] — Recruiting now
• A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus — Running, not enrolling
• A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. — Completed
• A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome — Running, not enrolling
• Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis — Completed
• Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis — Completed
• PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis — Completed
• Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis — Completed
• Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX — Completed
• A Study of Belimumab in Subjects With Systemic Lupus Erythematosus — Completed
• A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee — Completed
• Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA) — Completed